In contrast to other immune checkpoint components, PD‐L1 is rarely expressed in normal tissue but is induced in tumour‐associated tissue, is a tumour biomarker and is also an attractive drug target.113, 114 As many current treatment schemes are based on immunotherapy, pathological assessment should include immune checkpoint proteins. This evidence concerns the gene CD274 and neoplasm.